High Cholesterol

Cholesterol, both good and bad, gets plenty of attention when the subject is reducing the risk of heart disease. Yet triglycerides, a form of fat that circulates in the blood, merit similar attention.

Researchers examine whether an alternative approach to treating high blood cholesterol may provide an effective treatment option for patients who are unable or unwilling to take statins.

Farm-raised tilapia has very low levels of beneficial omega-3 fatty acids and very high levels of omega-6 fatty acids. The combination could be potentially dangerous for some patients with heart disease, arthritis, asthma and other allergic and auto-immune diseases.

Individuals in a prediabetic state who were treated with the oral medication pioglitazone were 81 percent less likely to convert to diabetes than those who received a placebo.

A study suggests the release of lipids from abdominal fat, which drains directly to the liver, increases overnight, providing additional insight as to how abdominal fat is associated with type 2 diabetes risk.

Researchers have identified a potential target for the development of new therapies to treat hypertriglyceridemia, a lipid disorder commonly seen in people who are obese and diabetic.

Higher concentrations of low-density lipoprotein (LDL) that has been modified by oxidation is associated with an increased incidence of abdominal obesity, high fasting glucose levels and high triglyceride levels and the metabolic syndrome, which includes a combination of these conditions.

Finding gives one more piece in the puzzle about the role of cholesterol in Parkinson's disease.

Aggressively lowering cholesterol and blood pressure levels below current targets in adults with type 2 diabetes may help to prevent - and possibly reverse - hardening of the arteries.

A comparison of two types of medications to treat type 2 diabetes finds that pioglitazone is more effective at lowering the rate of progression of plaque build-up in the coronary arteries than glimepiride, according to a study in the April 2 issue of JAMA.

The anti-obesity medication rimonabant showed mixed results in slowing progression of coronary artery disease in patients with abdominal obesity and pre-existing coronary disease, according to a new study in the April 2 issue of JAMA.

Researchers have discovered that many of the genetic variations that have enabled human populations to tolerate colder climates may also affect their susceptibility to metabolic syndrome.

A new study led by researchers at Joslin Diabetes Center has identified insulin resistance in the liver as a key factor in the cause of metabolic syndrome and its associated atherosclerosis.

A new study has discovered that supplements of lipoic acid can inhibit formation of arterial lesions, lower triglycerides, and reduce blood vessel inflammation and weight gain - all key issues for addressing cardiovascular disease.

Researchers have found a way to reduce the amount of bad cholesterol and fatty acids that end up in the blood from food the body metabolizes, a key discovery that could lead to new drugs to treat and reverse the effects of Type 2 diabetes and heart disease related to obesity.

A new review suggests that so far, only modest evidence supports the use of most medications to raise levels of high-density lipoprotein (good cholesterol).